HOTH - Hoth Therapeutics Inc Stock Price, Fair Value and News

$0.84+0.02 (+2.44%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

HOTH Price Action

Last 7 days

-3.4%

Last 30 days

-4.5%

Last 90 days

15.1%

Trailing 12 Months

-21.5%

HOTH RSI Chart

HOTH Valuation

Market Cap

5.8M

Price/Earnings (Trailing)

-0.77

Price/Sales (Trailing)

3.03

Price/Free Cashflow

-0.72

HOTH Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

HOTH Fundamentals

HOTH Revenue

Revenue (TTM)

2.0M

HOTH Earnings

Earnings (TTM)

-7.5M

Earnings Growth (Yr)

-2.18%

Earnings Growth (Qtr)

-30.6%

HOTH Profitability

Return on Equity

-100.18%

Return on Assets

-90.37%

Free Cashflow Yield

-138.32%

HOTH Investor Care

Shares Dilution (1Y)

58.84%

Diluted EPS (TTM)

-1.13

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	0	0	0
2022	2.5M	2.2M	2.0M	0
2021	2.5M	2.4M	2.3M	0
2020	2.6M	2.8M	2.8M	2.5M
2019	784.2K	1.1M	1.6M	2.1M
2018	0	0	0	682.9K
2017	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Hoth Therapeutics Inc

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; ZylÃƒÆ’Ã‚Â¶ Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.

CEO	Mr. Robb Knie
WEBSITE	hoththerapeutics.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	2

Hoth Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Hoth Therapeutics Inc? What does HOTH stand for in stocks?

HOTH is the stock ticker symbol of Hoth Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Hoth Therapeutics Inc (HOTH)?

As of Wed Nov 20 2024, market cap of Hoth Therapeutics Inc is 5.8 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HOTH stock?

You can check HOTH's fair value in chart for subscribers.

Is Hoth Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether HOTH is over valued or under valued. Whether Hoth Therapeutics Inc is cheap or expensive depends on the assumptions which impact Hoth Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HOTH.

What is Hoth Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Nov 20 2024, HOTH's PE ratio (Price to Earnings) is -0.77 and Price to Sales (PS) ratio is 3.03. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HOTH PE ratio will change depending on the future growth rate expectations of investors.